Quest Partners LLC Acquires 1,938 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Quest Partners LLC boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 27,685.7% in the third quarter, Holdings Channel reports. The institutional investor owned 1,945 shares of the medical equipment provider’s stock after buying an additional 1,938 shares during the period. Quest Partners LLC’s holdings in Lantheus were worth $213,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LNTH. Moloney Securities Asset Management LLC bought a new position in Lantheus during the 3rd quarter worth approximately $1,066,000. Hancock Whitney Corp increased its stake in shares of Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after acquiring an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at $290,000. Van ECK Associates Corp increased its stake in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares in the last quarter. Finally, Swedbank AB increased its stake in shares of Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after acquiring an additional 125,843 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $90.27 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock’s 50-day simple moving average is $102.48 and its 200 day simple moving average is $97.13. The stock has a market capitalization of $6.28 billion, a P/E ratio of 14.90 and a beta of 0.51.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Truist Financial reissued a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.